A fee schedule rate is not a durable price: coverage is the real asset

The headline number is the wrong thing to celebrate

Lucid Diagnostics says Medicare is paying $1,938.01 per EsoGuard test, the full fee schedule rate, and that October volume was a record. PAVmed, its parent, says Medicare has been paying Lucid since October. It is a good week for the company, and it should be read carefully.

The detail that matters sits further down the release. Coverage is being granted case by case, while a wider MolDX reconsideration remains pending. That is the difference between a price and a policy. A price tells you what one claim earns. A coverage decision tells you how many claims will be paid, for whom, and for how long. Until the reconsideration resolves, the $1,938.01 figure describes the best case for each approved claim, not a guaranteed revenue base.

Why this matters beyond one diagnostics company

Pharma and medtech executives routinely model pricing as a rate multiplied by volume. In practice, the volume term is set by coverage policy, and coverage policy moves on a slower and less predictable clock than commercial execution. Lucid can post record monthly volume and still depend on a pending determination to turn those claims into a stable franchise.

Its sister company shows the other side of the ledger. Veris Health has frozen its monitor design and started an animal study ahead of an early-2027 FDA 510(k) submission. That is clean, linear progress on regulatory risk. The reimbursement risk that follows clearance is not linear at all, and it will not be settled by a filing.

The enforcement backdrop is part of the pricing environment

The same week, the US Department of Justice announced that Daniel Lee, director of Queens SADC, pleaded guilty to conspiracy to commit health care fraud and money laundering. The scheme, worth $127m, involved claims for unnecessary prescription drugs and adult day care services never delivered.

The case has no connection to Lucid, and nothing in the material suggests otherwise. The link is structural. Medicare and Medicaid pay at scale, and they are also policed at scale. Case-by-case coverage, medical-necessity tests and documentation requirements exist partly because programs must separate legitimate claims from abusive ones. Every company that sells into these programs inherits that scrutiny, whether or not it has done anything to deserve it.

The strongest counter-argument

The best objection is that I am overreading a good-news story. Case-by-case coverage is how many new products enter reimbursement, and payment at the full fee schedule rate suggests the program is not haggling over price. A pending reconsideration is also an opportunity, not only a risk. Early paid claims build the record that a wider decision can rely on. On this view, Lucid is doing exactly what a young diagnostics company should do.

I agree with most of that. But it supports my argument rather than refuting it. If early paid claims are the evidence base for a wider decision, then claim quality, documentation and clinical justification are strategic assets, not back-office hygiene. The company that treats them as such is the one that benefits when the reconsideration lands.

What leaders should do

Stop reporting reimbursement wins as price wins. A rate is a ceiling; coverage breadth is the floor, and investors, partners and boards should be shown both. Treat every paid claim in a discretionary coverage regime as an exhibit in a future decision. And assume that the people who pay will examine how you were paid, because in this system they always do.

— The Editor, CompePharma